United Therapeutics CEO Sells $5 Million Worth of Shares
Martine A. Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ:UTHR), sold 9,500 shares on July 27, 2026, for a total value of $5 million under a pre-established Rule 10b5-1 trading plan adopted in November 2025. The transaction involved the exercise and immediate sale of stock options at a strike price of $135.42 per share, with proceeds based on an average sale price of $530.42. Rothblatt remains a major shareholder, holding over $353 million in equity post-transaction. The CEO's remaining shares are primarily held indirectly through family trusts and other accounts, totaling 628,215 shares valued at the July 27 market close of $527.94 per share. Rothblatt’s direct ownership remains unchanged at approximately 6% of total common stock interest. While insider selling can raise concerns among investors, this transaction appears to be part of a planned strategy rather than an indication of negative sentiment toward the company or its future prospects.
Tickers: $UTHR
Topics: CEO activity Rule 10b5-1 plan stock sale